Former Oxford 'golden boy' transplant surgeon's suspension extended
A "golden boy" transplant surgeon found to have sexually harassed female colleagues has had his eight-month suspension extended to a year.James Gilbert worked as a senior registrar in 2008 and 2009 for Oxford University Hospitals (OUH) NHS Trust and as a consultant between 2010 and 2022, when he was sacked.One woman said his status was the "golden boy" of the department and that he was the "be-all and end-all for transplants in Oxford".A Medical Practitioners Tribunal Service (MPTS) panel found Mr Gilbert sexually harassed four women but the General Medical Council (GMC) appealed the suspension's length at the High Court on Thursday.
The GMC, supported by the Professional Standards Authority for Health and Social Care (PSA), said the eight-month suspension was "insufficient to protect the public".Mr Justice Calver imposed a 12-month suspension, the longest possible, and said the MPTS's had erred twice at Mr Gilbert's tribunal in August.The judge found the doctor imitating an Indian accent and telling a man "oh, when are you leaving the country now?", or words to that effect, and referring to Brexit was racist.He also found Mr Gilbert telling a colleague "look at all that fat, this is what happens when you eat chapatti" during an organ retrieval procedure constituted harassment.The MPTS panel had previously found that those charges were not proved.In other claims, he reportedly said to one trainee while working in Oxford: "You're a well together girl, you must always wear matching underwear. What kind are you wearing now?"Another trainee was allegedly asked about matching underwear, and on one occasion he reportedly stared at her and said: "I have been watching you and you're pretty perfect."
In May 2021, OUH excluded Mr Gilbert after concerns were raised but he was allowed to return six weeks later with restrictions on his practice.An email was then sent to surgical trainees inviting them to flag up concerns, leading to Mr Gilbert's dismissal in May 2022.Mr Justice Calver said the 12-month suspension "reflects the seriousness" of Mr Gilbert's misconduct.He added it will also give Mr Gilbert "an adequate period to reflect upon and remediate his behaviour" but that it was "not suggested that Mr Gilbert was other than a highly competent surgeon".Mr Gilbert told the MPTS that the disciplinary process had been "humbling, humiliating and deeply shameful".He said he was a "different person and a fundamentally changed practitioner from the doctor whose conduct led to [the] complaints being raised" and apologised for his behaviour.
You can follow BBC Oxfordshire on Facebook, X (Twitter), or Instagram.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South Wales Argus
a day ago
- South Wales Argus
UK safari park announces the birth of three lion cubs
The cubs arrived in April to 12-year-old Amber, and have just had their first health checks, confirming two males and a female. West Midlands Safari Park's veterinary team and keepers have named them Nero, Nox, and Nancy. The next steps for the cubs will be an introduction to the outside world, with the keepers allowing them access to an outdoor area, next to the lion house. Just like a domestic cat, the lion cubs will need their second lot of injections and another health check before they are allowed to venture into the great outdoors to meet guests. The birth of the cubs is significant as lions are classed as 'vulnerable' in the wild by the International Union for the Conservation of Nature. The lion cubs' arrival follows a recent baby boom at the park, including three Sumatran tiger cubs, an Indian rhino calf, two blesbok calves, and a barasingha fawn.
Reuters
a day ago
- Reuters
India's OneSource eyes weight-loss drug boost to order book
June 12 (Reuters) - Indian contract drug manufacturer OneSource Specialty Pharma ( opens new tab expects strong growth in its order book over the next three years, driven by the global boom in weight-loss drugs, its top executive said on Monday. Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk ( opens new tab and U.S.-based Eli Lilly (LLY.N), opens new tab. The active chemical compound in Novo's injectable Wegovy drug, semaglutide, will go off patent in 2026 in a few markets, including India. OneSource, which added 15 orders related to obesity and diabetes drugs in fiscal year 2025, said there are more in the pipeline. The global obesity market is estimated to be valued at $150 billion by the early 2030s. The company develops and manufactures complex biological drugs, vials, injectables, and soft gelatin capsules for larger pharmaceutical firms. "Our growth over the next few years will be driven by commercial launches of GLP-1s (weight-loss and diabetes drugs) by our global customers in all the key markets opening post patent expiry in 2026," CEO Neeraj Sharma told Reuters in an interview. Backed by increasing demand from weight-loss drug manufacturers, OneSource's order book across all service verticals should expand in line with 30% compound annual growth rate through fiscal year 2028, according to the CEO. OneSource, which competes with larger players such as Piramal Pharma ( opens new tab and Divi's ( opens new tab in contract research, development and manufacturing, is investing about $100 million to expand its drug device facilities, the CEO said. The company, which was demerged from Strides Pharma Science ( opens new tab and listed in January, is also looking at setting up a global footprint in manufacturing, both in Europe and the U.S.
North Wales Chronicle
2 days ago
- North Wales Chronicle
No disciplinary sanction for doctor's ‘grave' failures in care of Martha Mills
Professor Richard Thompson did not refer Martha Mills, 13, to intensive care despite her displaying several high-risk indicators of sepsis. The on-call consultant also chose not to return to London's King's College Hospital to assess her in person as her condition deteriorated. A Medical Practitioners Tribunal Service (MPTS) panel sitting in Manchester had ruled those omissions were misconduct, which they described as 'particularly grave', and found his fitness to practise was impaired. However, on Wednesday the tribunal decided there were 'exceptional circumstances' which justified taking no further action against the world-renowned paediatric liver specialist. Martha had been an inpatient on the hospital's Rays of Sunshine Ward after she suffered a serious injury to her pancreas when she slipped while riding a bike on a family holiday in Wales in July 2021. Weeks later she experienced a fever and increased heart rate, followed by more spikes in her temperature before the consultant hepatologist saw Martha on his morning ward round on Sunday August 29. Prof Thompson left the hospital at 3pm, but was phoned at home two hours later by a trainee doctor, who gave an update on Martha's condition. Medical records showed she had deteriorated over the course of the afternoon, and into the early evening, with a drop in her blood pressure, the appearance of a new rash and increases in heart rate, respiratory rate and body temperature. Tribunal chairman Robin Ince noted that by 5pm there were 'several high-risk indicators' as set out in the Nice guidelines relating to sepsis. The duty registrar called Prof Thompson again at 8.30pm because of ongoing concerns over Martha's fever, but she was kept on the ward despite the continued presence of moderate to high-risk indicators and the absence of meaningful clinical improvement. Martha collapsed on August 30 and was moved to intensive care before she was transferred to London's Great Ormond Street Hospital, where she died in the early hours of August 31. Announcing its conclusions on Wednesday, Mr Ince said: 'Professor Thompson has done everything possible to address his failings. 'The tribunal considered that the best way to repair any harm caused by his failings would be for him to continue to provide his specialist expertise at home and abroad. 'To now – some four years after the index event – remove Professor Thompson from practice, even for a short period of time, for one single lapse of judgment in an otherwise exemplary career would, in the tribunal's view, be akin to punishment which is not the role of the MPTS.' Among the 'exceptional circumstances' cited were that there was no allegation or evidence that Prof Thompson either caused or contributed to Martha's death. There were also systemic failings regarding how the ward functioned at the time with regard to referrals to the paediatric intensive care unit, said the tribunal. Mr Ince said: 'A sufficiently clear message has already been sent to the profession and to the public – that even such an experienced doctor as Professor Thompson could still make serious errors of clinical judgment for which he will be called to account. 'The public would be aware that this finding would remain a stain on Professor Thompson's reputation for the rest of his life.' At a 2022 inquest into her death, a coroner ruled that Martha would most likely have survived if doctors had identified the warning signs and transferred her to intensive care earlier. Martha's mother, Merope Mills, an editor at The Guardian, said she and her husband, Paul Laity, raised concerns about Martha's deteriorating health a number of times but these were not acted on. The couple later successfully campaigned for Martha's Rule to give patients, families and carers the chance to easily request a second opinion from a senior doctor in the same hospital in the event of a suspected deterioration or serious concern. Giving evidence, Prof Thompson told the MPTS hearing that he no longer provided in-patient care because he began to 'doubt my own judgment' after the tragic events. He said he felt 'deep remorse' for Martha's death but did not believe he made any errors in her case, as he denied all the allegations brought by the General Medical Council (GMC). The tribunal heard he had since completed a training course relating to the management of sepsis and a deteriorating child in paediatric care. His barrister, Ben Rich, said Prof Thompson has been a dedicated doctor and specialist for nearly 40 years and had never previously been investigated by a regulator. He said he had a reputation as a 'hard-working and outstanding clinician and researcher, who has an international reputation as one of the leading paediatric liver specialists in the world'. Mr Rich urged the tribunal members to impose an order of conditions involving supervision on Prof Thompson's registration, but the panel disagreed and said such a measure would be 'unnecessary and artificial', as they opted to take no further action. Christopher Rose, for the GMC, said that Prof Thompson should be suspended to send a message to the wider public and the wider profession, given the seriousness of the failings found. The tribunal had cleared Prof Thompson of the GMC's claims that he gave 'outdated, misleading' information on Martha's condition to a consultant colleague in the intensive care unit, and that he failed to mention her rash. In ruling his fitness to practise was impaired, Mr Ince said: 'There had been a significant potential risk of harm to Martha and it was appropriate to send a message to the profession as to the importance of following the basic and fundamental principles as set out in good medical practice so as to ensure that the potential risks of an adverse outcome are always taken into account.'
